Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We investigated the relationship between mefloquine antimalarial treatment and the outcome of pregnancy in Karen women living in an area along the western border of Thailand where multidrug-resistant Plasmodium falciparum infections are common. Of 3,587 pregnancies investigated, 208 (5.8%) were exposed to mefloquine, 656 (18.3%) to quinine only, and 909 (25.3%) to other antimalarials, and 2,470 (68.9%) had no documented malaria. There were 61 stillbirths and 313 abortions. Women who received mefloquine treatment during but not before pregnancy had a significantly greater risk of stillbirth than did women treated with quinine alone (odds ratio [OR], 4.72; 95% confidence interval [CI], 1.7-12.7), women exposed to other treatments (OR, 5.10; 95% CI, 2-13.1), and women who had no malaria (OR, 3.50; 95% CI, 1.6-7.6) (P < .01). This association remained after adjustment for all identified confounding factors. Mefloquine was not associated with abortion, low birth weight, neurological retardation, or congenital malformations. Mefloquine treatment during pregnancy was associated with an increased risk of stillbirth.

Original publication

DOI

10.1086/515183

Type

Journal article

Journal

Clin Infect Dis

Publication Date

04/1999

Volume

28

Pages

808 - 815

Keywords

Abnormalities, Drug-Induced, Abortion, Spontaneous, Adult, Antimalarials, Female, Fetal Death, Humans, Infant, Low Birth Weight, Infant, Newborn, Malaria, Falciparum, Mefloquine, Pregnancy, Pregnancy Complications, Parasitic, Pregnancy Outcome, Risk Factors, Surveys and Questionnaires, Treatment Outcome